These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25484311)

  • 41. FDA regulation of allogeneic islets as a biological product.
    Weber DJ
    Cell Biochem Biophys; 2004; 40(3 Suppl):19-22. PubMed ID: 15289639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.
    Wood D; Wesselschmidt R; Hematti P; Gee AP; Rooney C; Silberstein L; Armant M; Couture L; Wagner JE; McKenna DH; Hei D; Mondoro TH; Welniak L; Lindblad R
    Clin Transl Sci; 2014 Apr; 7(2):93-9. PubMed ID: 24655892
    [No Abstract]   [Full Text] [Related]  

  • 44. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Implementation of cardovascular cell therapy network trials: challenges, innovation and lessons learned from experience in the CCTRN.
    Park KE; Moyé LA; Henry TD; Perin EC; Sayre SL; Bettencourt J; Vojvodic RW; Olson RE; Pepine CJ;
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1495-502. PubMed ID: 24147517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.
    Matthay MA; Anversa P; Bhattacharya J; Burnett BK; Chapman HA; Hare JM; Hei DJ; Hoffman AM; Kourembanas S; McKenna DH; Ortiz LA; Ott HC; Tente W; Thébaud B; Trapnell BC; Weiss DJ; Yuan JX; Blaisdell CJ
    Am J Respir Crit Care Med; 2013 Aug; 188(3):370-5. PubMed ID: 23713908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Appropriate specifications at the IND stage.
    Geigert J
    PDA J Pharm Sci Technol; 1997; 51(2):78-80. PubMed ID: 9146038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
    Sutherland V; Buffo MJ; Whiteside TL
    Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs.
    Abou-El-Enein M; Römhild A; Kaiser D; Beier C; Bauer G; Volk HD; Reinke P
    Cytotherapy; 2013 Mar; 15(3):362-83. PubMed ID: 23579061
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.
    Berro M; Burnett BK; Fromell GJ; Hartman KA; Rubinstein EP; Schuff KG; Speicher LA;
    Acad Med; 2011 Feb; 86(2):217-23. PubMed ID: 21169787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.
    Fogli LK; Aurigemma R; Sommers CL; Singh A; Bourcier K; Ernstoff MS;
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34266886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges associated with the development, manufacturing, and delivery of cellular medicines.
    Preti RA
    Cancer J; 2001; 7 Suppl 2():S62-6. PubMed ID: 11777266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The Contribution of GMP-grade Hospital Preparation to Translational Research].
    Yonezawa A; Kajiwara M; Minami I; Omura T; Nakagawa S; Matsubara K
    Yakugaku Zasshi; 2015; 135(8):943-7. PubMed ID: 26234351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 59. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.